ARGX — argenx SE

Summary of ARGX Q3 2025 Earnings Call

1. Key Financial Results and Metrics

• Total Product Net Sales: $1.13 billion, a historic milestone surpassing $1 billion for the first time in a single quarter.
  • Quarter-over-Quarter Growth: 19% ($178 million increase).
  • Year-over-Year Growth: 96% ($554 million increase).
  • Regional Breakdown:
    • U.S.: $964 million
    • Japan: $60 million
    • Rest of World: $94 million
    • China (Zai Lab): $9 million
• Operating Expenses: $805 million, a 5% increase from Q2.
  • R&D Expenses: Increased by 9% ($28 million).
  • SG&A Expenses: Increased by 4% ($11 million).
• Operating Profit: $346 million.
• Net Profit: $344 million for the quarter, with a year-to-date profit of $759 million.
• Cash Position: $4.3 billion, a nearly $1 billion increase since the start of the year.

2. Strategic Updates and Business Highlights

• Product Development: VYVGART is now approved in most major markets, with a focus on two blockbuster indications: Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
• Pipeline Progress:
  • Three first-in-class molecules in Phase III development.
  • Four new molecules expected in Phase I by year-end.
  • Positive data from studies supporting VYVGART's efficacy and safety, including significant improvements in MG-ADL scores.
• Commercial Strategy:
  • The prefilled syringe (PFS) has driven new patient adoption, with over 50% of new patients starting on PFS.
  • Expansion into new indications and markets, including plans for label expansions in seronegative MG and ocular MG.

3. Forward Guidance and Outlook

• Operating Expenses: Expected to grow in the single digits for the remainder of the year, with combined R&D and SG&A expenses projected to exceed $2.5 billion.
• Upcoming Milestones: Anticipating five registrational readouts in 2026, including ocular MG, myositis, and thyroid eye disease (TED).
• Long-Term Vision: Committed to Vision 2030, focusing on sustainable growth and expanding the pipeline.

4. Bad News, Challenges, or Points of Concern

• Discontinuation of Programs: Stopped development of empasiprubart in dermatomyositis due to enrollment challenges, and decided against advancing efgartigimod into a registrational study for lupus nephritis based on Phase II results.
• Competitive Pressures: Notable competition from other companies, including a head-to-head trial announced by J&J for a competing product in MG.
• Enrollment Challenges: Concerns regarding enrollment in certain trials, particularly for empasiprubart in dermatomyositis and the need for robust data to support new indications.

5. Notable Q&A Insights

• Formulation Mix: The PFS is driving growth, but other formulations (IV and Hytrulo) continue to contribute positively.
• Market Dynamics: Strong demand for CIDP and MG treatments, with a significant number of new prescribers adopting VYVGART.
• Seronegative MG Opportunity: Confidence in the commercial potential based on positive trial results, with a focus on addressing the needs of underserved patient populations.
• Future Indications: Discussions around potential for VYVGART in Graves' disease and TED, with excitement about the commercial opportunity in these areas.
• Patient Experience: Positive feedback from patients and prescribers regarding the convenience of the PFS and its impact on treatment adherence and quality of life.

Overall, ARGX reported a strong quarter with significant sales growth, strategic advancements in its pipeline, and a clear focus on expanding its market presence, despite facing challenges related to competitive pressures and certain program discontinuations.